Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Gynecologic Oncology Group Identifier:
First received: April 7, 2003
Last updated: July 8, 2013
Last verified: July 2007

RATIONALE: Amifostine may be effective in relieving numbness, tingling, and other symptoms of peripheral neuropathy. It is not yet known whether amifostine is effective in treating peripheral neuropathy in patients who have received chemotherapy for cancer.

PURPOSE: This randomized phase III trial is studying amifostine to see how well it works compared to observation in relieving numbness, tingling, and other symptoms of peripheral neuropathy in patients who have received platinum-based chemotherapy (such as cisplatin or carboplatin) for cancer.

Condition Intervention Phase
Gestational Trophoblastic Tumor
Peripheral Neuropathy
Unspecified Adult Solid Tumor, Protocol Specific
Drug: amifostine trihydrate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Supportive Care
Official Title: A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy

Resource links provided by NLM:

Further study details as provided by Gynecologic Oncology Group:

Primary Outcome Measures:
  • Improvement of neuropathy by WEST assessment at 6, 12, 18, and 24 weeks

Secondary Outcome Measures:
  • Improved quality of life by Functional Assessment of Cancer Therapy-GOG/NTX (FACT-GOG/NTX) at 6, 12, 18, and 24 weeks

Estimated Enrollment: 100
Study Start Date: March 2003
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine, preliminarily, whether amifostine is superior to no treatment, in terms of improving the symptoms and/or objective findings of platinum-induced peripheral neuropathy, in patients with cancer.
  • Determine the toxicity of this drug in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive amifostine IV or subcutaneously over 3 minutes on days 1, 3, and 5. Treatment continues for 12 weeks in the absence of unacceptable toxicity. Patients are observed for 12 weeks.
  • Arm II: Patients are observed for 24 weeks. After 24 weeks patients may cross over to treatment as in arm I.

Quality of life is assessed at baseline and then at 6, 12, 18, and 24 weeks after study entry.

Patients are followed at 6 and 12 weeks after study treatment, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 50-100 patients (25-50 per treatment arm) will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Prior therapy with platinum-based chemotherapy regimen for a malignancy

    • Treatment with other agents, including paclitaxel, allowed
  • Grade 2 or greater peripheral neuropathy (numbness, tingling, pain in the distal extremities) attributed to prior platinum-based chemotherapy

    • Must have persisted and be stable for 3-36 months after completion of chemotherapy
    • Duration of neuropathy no more than 3 years
  • No other possible causes for the neuropathy (e.g., alcoholism, diabetes, or peripheral vascular disease)



  • 18 and over

Performance status

  • GOG 0-3

Life expectancy

  • At least 6 months


  • Not specified


  • Bilirubin no greater than 2.0 mg/dL


  • Creatinine no greater than 2.0 mg/dL
  • Calcium at least lower limit of normal


  • No hypotension
  • No history of cerebrovascular accident


  • No other significant comorbid medical conditions that would preclude study participation


Biologic therapy

  • Not specified


  • See Disease Characteristics
  • No concurrent chemotherapy
  • No chemotherapy (including paclitaxel, cisplatin, and carboplatin) for at least 4 months after study entry

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified


  • At least 24 hours since prior antihypertensive medications
  • No prior amifostine
  • Prior treatment on a GOG treatment protocol allowed
  • No concurrent monoamine oxidase inhibitors
  • No concurrent neurotoxic agents during and for at least 6 months after study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00058071

  Show 57 Study Locations
Sponsors and Collaborators
Gynecologic Oncology Group
National Cancer Institute (NCI)
Study Chair: Steven C. Plaxe, MD University of California, San Diego
  More Information

Additional Information:
No publications provided Identifier: NCT00058071     History of Changes
Other Study ID Numbers: CDR0000285700, GOG-0192
Study First Received: April 7, 2003
Last Updated: July 8, 2013
Health Authority: United States: Federal Government

Keywords provided by Gynecologic Oncology Group:
peripheral neuropathy
hydatidiform mole
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Peripheral Nervous System Diseases
Gestational Trophoblastic Disease
Neurotoxicity Syndromes
Trophoblastic Neoplasms
Chemically-Induced Disorders
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Nervous System Diseases
Neuromuscular Diseases
Pregnancy Complications
Pregnancy Complications, Neoplastic
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Protective Agents processed this record on November 27, 2015